Allogene Therapeutics, Inc. is a company in the U.S. stock market and it is a holding in 55 U.S.-traded ETFs. ALLO has around 6.9M shares in the U.S. ETF market. The largest ETF holder of ALLO is the SPDR S&P Biotech ETF (XBI), with approximately 1.53M shares. Investors may also find of interest that the ETF with the largest allocation to ALLO stock is Global X Genomics & Biotechnology ETF (GNOM), with a portfolio weight of 2.81%. On average, U.S. ETFs allocate 0.33% of ALLO to their portfolios.
Additionally, ALLO is a favorite stock for Vanilla and Multi-factor ETFs. It is also most likely to belong to Broad-based ETFs. The best-performing ETF in the past 12 months with ALLO as a holding is the Renaissance IPO ETF (IPO), with a return of 68.70%.